Clinical Trials Logo

Clinical Trial Details — Status: Available

Administrative data

NCT number NCT02065674
Other study ID # ABROAGUS01
Secondary ID
Status Available
Phase Phase 2
First received February 13, 2014
Last updated June 5, 2015
Start date February 2014
Est. completion date December 2014

Study information

Verified date June 2015
Source Fr Muller Homoeopathic Medical College
Contact dr rita chakraborty, MD
Phone +919448309048
Email ritapranab@gmail.com
Is FDA regulated No
Health authority India: Institutional Review BoardIndia: Indian Council of Medical Research
Study type Expanded Access

Clinical Trial Summary

Objective: To ascertain whether homoeopathic medicine ABROMA AUGUSTA has a clinical role in changing the Glycated Hb Level in Diabetes mellitus Type II.

Abstract:

Background: Type 2 diabetes mellitus (T2DM) is one of the most important epidemic diseases in the world in this century, and accounts for 90% of cases of diabetes globally. Studies have suggested that Abroma Augusta plays a role in acute controlling blood glucose level. The aim of this study was to evaluate the efficacy of "Abroma Augusta Ѳ" in chronic control through GlycatedHb (HbA1c %) in Diabetes Mellitus Type 2 (NIDDM) as a pretest post-test study.


Description:

Introduction:

Diabetes mellitus type 2 (noninsulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes) is a metabolic disorder that is characterized by hyperglycemia (high blood sugar) in the context of insulin resistance and relative lack of insulin. According to recent survey reports about 5% of the total world population is suffering from Diabetes Mellitus. The incidence rate is also reasonably high in India. Currently about 20% of Indian Population is at High risk to develop Diabetes Mellitus in future i.e. they are having abnormal glucose Tolerance test. Studies have revealed that diabetic women suffer more than men. Diabetes is the single most important metabolic disease which can affect nearly every organ system in the body. According to the World Health Organization estimates, India had 32 million diabetic subjects in the year 2000 and this number would increase to 80 million by the year 2030. The International Diabetes Federation (IDF) also reported that the total number of diabetic subjects in India is 41 million in 2006 and that this would rise to 70 million by the year 2025. A male who is diabetic has double the chances of heart failure. In case of women it grows to almost 5 times and it is 8 times more if the patient is a young female.

The prevalence of diabetes is rapidly rising all over the globe at an alarming rate1 . Over the past 30 yr, the status of diabetes has changed from being considered as a mild disorder of the elderly to one of the major causes of morbidity and mortality affecting the youth and middle aged people. It is important to note that the rise in prevalence is seen in all six inhabited continents of the globe2 . Although there is an increase in the prevalence of type 1 diabetes also, the major driver of the epidemic is the more common form of diabetes, namely type 2 diabetes, which accounts for more than 90 per cent of all diabetes cases. Nowhere is the diabetes epidemic more pronounced than in India as the World Health Organization (WHO) reports show that 32 million people had diabetes in the year 2000. The International Diabetes Federation (IDF) estimates the total number of diabetic subjects to be around 40.9 million in India and this is further set to rise to 69.9 million by the year 2025.

Long-term complications of diabetes develop gradually. The longer you have diabetes — and the less controlled your blood sugar — the higher the risk of complications. Eventually, diabetes complications may be disabling or even life-threatening. Possible complications include:

- Cardiovascular disease.Diabetes dramatically increases the risk of various cardiovascular problems, including coronary artery disease with chest pain (angina), heart attack, stroke and narrowing of arteries (atherosclerosis).

- Nerve damage (neuropathy). Excess sugar can injure the walls of the tiny blood vessels (capillaries) that nourish your nerves, especially in your legs. This can cause tingling, numbness, burning or pain that usually begins at the tips of the toes or fingers and gradually spreads upward. Left untreated, you could lose all sense of feeling in the affected limbs. Damage to the nerves related to digestion can cause problems with nausea, vomiting, diarrhea or constipation. For men, it may lead to erectile dysfunction.

- Kidney damage (nephropathy). The kidneys contain millions of tiny blood vessel clusters (glomeruli) that filter waste from your blood. Diabetes can damage this delicate filtering system. Severe damage can lead to kidney failure or irreversible end-stage kidney disease, which may require dialysis or a kidney transplant.

- Eye damage (retinopathy). Diabetes can damage the blood vessels of the retina (diabetic retinopathy), potentially leading to blindness. Diabetes also increases the risk of other serious vision conditions, such as cataracts and glaucoma.

- Foot damage. Nerve damage in the feet or poor blood flow to the feet increases the risk of various foot complications. Left untreated, cuts and blisters can develop serious infections, which often heal poorly. These infections may ultimately require toe, foot or leg amputation.

- Skin conditions. Diabetes may leave you more susceptible to skin problems, including bacterial and fungal infections.

- Hearing impairment. Hearing problems are more common in people with diabetes.

- Alzheimer's disease. Type 2 diabetes may increase the risk of Alzheimer's disease. The poorer your blood sugar control, the greater the risk appears to be. Although there are theories as to how these disorders might be connected, none has yet been proved.

So Diabetes is associated with long term complications that affect almost every major part of the body. Type 2 diabetes is initially managed by increasing exercise and dietary changes. If blood sugar levels are not adequately lowered by these measures, medications or intervention is needed. In those on medication, there is absolute requirement of routinely check up of blood sugar levels.

There is good number of Homoeopathic medicine to control blood sugar level. They are Cephalandra Indica, Syzegium, Gymnema Sylvestree, Abroma Augusta, Rhus Aromatica rtc. It is noticed that the blood sugar (HbA1c) is not controlled by other system of medicine; the patients come for Homoeopathic treatment and after homoeopathic treatment there is a remarkable improvement in FBS, PPBS as well as HbA1c along with the general improvement of health like tiredness, lethargy, numbness, polyurea, polydypsia and polyphagia etc. But there is no scientific validation for that. Among those Abroma Augusta is selected for this study and this study is conducted for achieving the scientific validation, the homoeopathic hypoglycemic "Abroma Augusta".

ABROMA AUGUSTA Family: Sterculiaceae Bengali/vernacular name: Ulatkambal. Tribal name: Polumaoeba (Chakma); Daiya (Garo). English name: Devil's Cotton. Usually it has been used widely as an emmenagogue but its glycemic use is rare. Abroma Augusta commonly known as Olat Kambal. The plant of Abroma Augusta grows wild throughout the hotter part of India. In ancient times, it was used therapeutically as an emmenagogue in menstrual disorders. Late Dr. D.N.Roy of Calcutta proved this drug. A tincture of the drug is prepared from its leaves according to class III of American Homeopathic Pharmacopoea. It is used in diabetes insipidus with very gratifying results. Clinically it is indicated in Diabetes, albuminuria, enuresis, debility, vertigo, sleeplessness, carbuncle, amenorrhoea and dysmenorrhoea.

Description of the plant: ABROMA AUGUSTA L. is a large shrub. Leaves large, 10-15 by 10-12.5 cm, repand - denticulate, upper smaller, narrower, entire. Flower is solitary, auxiliary, pendulous, peduncle up to 4 cm long; sepals 2.5 cm, lanceolate; petals scarcely exceeding the sepals, dark red.

Chemical constituents:

Leaves contain taraxerol, its acetate and β-sitosterol. Stem bark contains friedelin and β-sitosterol. Root and root bark contain gum, fixed oil, resin, alkaloids, abromine, choline and betaine, β-sitosterol, stigmasterol, digitonide, magenesium salts of hydroxyl acids and polysaccharide. Seeds contain 20.2% fixed oil with 71.5% linoleic acid. Augustic acid an oleanane derivative and a stigmasterol glycoside have been isolated from the roots. Heartwood contains β-sitosterol, glycol and octacosane-1, 28-diol (Ghani, 2003; Rastogi & Mehrotra, 1993; Asolkar et al., 1992). Among them Taraxerol is the most important component which has hypoglycemic as well as anti-inflammatory action. It also contains flavinoid & phenolic component and they are phyto- antioxidant.

Homoeopathic uses: Fragmentary proving was conducted by Dr. D.N. Ray of Calcutta in 1919 and Dr. Jugal Kishore of New Delhi in 1972. It has been subsequently proved by CCRH and has shown its affinity for female reproductive organs producing symptoms of dysmenorrhoea and leucorrhoea, which have been confirmed during verification trials too.

Diabetes mellitus - Urine profuse < at night and of high specific gravity. Excessive thirst with dryness of mouth. Patient suffers from insomnia and prostration, and patient is averse to do any physical and intellectual labour. Mentally patient is of irritable nature, forgetful and morose.

Dysmenorrhoea - Colicky pains in lower abdomen. Menses are irregular, lasting for short or long time. Blood is dark and clotted.

There is lots of study on Aboma Augusta in modern system of Medicie as well as the Ayurveda on Rats and it was proved that this drug has not only the hypoglycemic effect (Taraxerol) but also has effect on antioxidant and lipid control. So this study was conducted to investigate the therapeutic efficacy on Human being.


Recruitment information / eligibility

Status Available
Enrollment 0
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 30 Years to 85 Years
Eligibility Inclusion Criteria:

Inclusion Criteria Age 30 Years above Both Sexes NIDDM FBS - 110-300mg/dl HbA1c above = 6.5

Exclusion Criteria:

- Patient with major complications like diabetic retinopathy and cardiomyopathy. IDDM HbA1c above 11%

Study Design

N/A


Intervention

Drug:
Abroma Augusta Q (mother tincture)
30 drops in 1 cup of water three times a day for 3 months

Locations

Country Name City State
India ,Father Muller Homoeopathic Medical College, Prasanth Nivas Ashram Nmpt Hospital Mangalore Karnataka

Sponsors (1)

Lead Sponsor Collaborator
Fr Muller Homoeopathic Medical College

Country where clinical trial is conducted

India, 

See also
  Status Clinical Trial Phase
Completed NCT01952535 - A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers Phase 1
Completed NCT01196728 - Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes Phase 1
Terminated NCT00997152 - Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients Phase 2
Completed NCT02592421 - SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2 Phase 3
Completed NCT05544214 - Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects Phase 1
Completed NCT01969084 - The Effect of Linagliptin on Mitochondrial and Endothelial Function Phase 4
Terminated NCT01644201 - A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics Phase 3
Completed NCT01020123 - Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients Phase 2
Completed NCT00995787 - Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea Phase 1
Completed NCT01505426 - A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients Phase 3
Completed NCT01262586 - Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device. Phase 3
Completed NCT00561171 - Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria Phase 2
Active, not recruiting NCT03912363 - Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids N/A
Completed NCT01868646 - Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus Phase 4
Active, not recruiting NCT06386328 - A Clinical Trial to Evaluate the Food Effect of CKD-378 Phase 1
Terminated NCT02749435 - A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus N/A
Completed NCT00894868 - Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure Phase 4
Recruiting NCT01165190 - Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans N/A
Completed NCT01255085 - Yellow Pea Protein and Fibre and Short Term Food Intake N/A
Completed NCT02156349 - A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients. N/A